tiprankstipranks
Summit Therapeutics: Promising Clinical Developments and Financial Stability Drive Buy Rating
PremiumRatingsSummit Therapeutics: Promising Clinical Developments and Financial Stability Drive Buy Rating
15d ago
Summit Therapeutics: Buy Rating Amid Promising Clinical Trials and Market Opportunities
Premium
Ratings
Summit Therapeutics: Buy Rating Amid Promising Clinical Trials and Market Opportunities
15d ago
Summit Therapeutics Reports Q1 2025 Progress and Financials
Premium
Company Announcements
Summit Therapeutics Reports Q1 2025 Progress and Financials
16d ago
Summit Therapeutics selloff Friday on data overdone, says H.C. Wainwright
PremiumThe FlySummit Therapeutics selloff Friday on data overdone, says H.C. Wainwright
19d ago
Summit Therapeutics Receives Buy Rating Amid Promising Ivonescimab Developments and Strategic Trials
Premium
Ratings
Summit Therapeutics Receives Buy Rating Amid Promising Ivonescimab Developments and Strategic Trials
22d ago
BMO says Keytruda ‘still reigns’ after ivonescimab survival data
Premium
The Fly
BMO says Keytruda ‘still reigns’ after ivonescimab survival data
22d ago
Summit Therapeutics says new ivonescimab data clinically meaningful
PremiumThe FlySummit Therapeutics says new ivonescimab data clinically meaningful
22d ago
Wells says Summit, Akeso data ‘not the bull case,’ but not ‘bear case either’
Premium
The Fly
Wells says Summit, Akeso data ‘not the bull case,’ but not ‘bear case either’
22d ago
Akeso reports ivonescimab receives NMPA approval to treat NSCLC in China
Premium
The Fly
Akeso reports ivonescimab receives NMPA approval to treat NSCLC in China
22d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100